Strides Pharma Science Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,430 Cr +17.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
SP

Strides Pharma Science Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Strides Pharma Science Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,323Cr
+11.2% YoY
+10.7% QoQ
Net profit
₹129Cr
+50% YoY
−38% QoQ
Margin
18%
0 pp YoY
−2 pp QoQ

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹986
Market cap₹8.9K Cr
P/E15.4

The short version

U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).

From Strides Pharma Science Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • U.S. business growth expected to accelerate from H2 FY27 onwards with new product launches, including nasal sprays and controlled substances.
  • Targeted U.S. revenue aspiration of $375 million to $400 million by FY28, representing about 15%-20% CAGR from current base.
  • Controlled substances business is a new growth engine; additional quota allocations pending with DEA may drive future growth.
  • Nasal sprays and complex generics (transdermals, films) expected to contribute meaningfully from FY28 and FY29 onwards.
  • Ex-U.S. markets showing strong, consistent growth with 21% CAGR in FY26 and growing faster than the U.S. market.

2 more points from Strides Pharma Science Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Total capital investments in FY26 were INR418 crores, including:
  • INR236 crores tangible capex focused on:
  • Nasal spray capabilities development
  • Enhancing capacities for Ex-U.S. business
  • Acquisition of new office space in the U.K.
  • INR182 crores intangible investments covering:
  • Acquisition of global product rights to drive growth in U.S. and Ex-U.S. markets
  • Significant upgrade to global ERP platform migrating to SAP HANA
  • Future capex run rate expected around INR300 crores annually over next 2 years:
  • Tangible capex largely maintenance capex after recent growth investments
  • Intangible investments expected to continue for acquiring global rights and fast-tracking growth

2 more points from Strides Pharma Science Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Strides Pharma Science Ltd said on order book & pipeline — free account, 30 seconds.

Strides Pharma Science Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Strides Pharma Science Ltd Q4 FY26 results — key figures

Strides Pharma Science Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,3231,190+11.2%1,195+10.7%
Operating profit (EBITDA)240218+10.1%236+1.7%
Operating margin18%18%0 pp20%-2 pp
Profit before tax148106+39.6%245-39.6%
Net profit (PAT)12986+50%208-38%
EPS (₹)13.778.91+54.5%21.93-37.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Strides Pharma Science Ltd Q4 FY26 results?

U.S. Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business).

What is Strides Pharma Science Ltd share price analysis?

Strides Pharma Science Ltd currently shows a below-average growth signal. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.

Is Strides Pharma Science Ltd planning capital expenditure?

Total capital investments in FY26 were INR418 crores, including: - INR236 crores tangible capex focused on: - Nasal spray capabilities development - Enhancing capacities for Ex-U.S.

Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.